Insmed Incorporated (Nasdaq: INSM), a US-based global biopharmaceutical company, announced on Wednesday that it has priced an underwritten public offering of 7,812,500 shares of its common stock at a price to the public of USD96.00 per share.

Gross proceeds to Insmed from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Insmed, are expected to be approximately USD750m. In addition, Insmed has granted the underwriters a 30-day option to purchase up to an additional 1,171,875 shares of common stock.

Insmed intends to use the net proceeds from this offering to fund continued research and development of brensocatib, as well as pre-commercial and, if approved, commercialisation activities related to brensocatib, activities related to the further commercialisation and development of ARIKAYCE (amikacin liposome inhalation suspension), further research and development of treprostinil palmitil inhalation powder (TPIP), INS1201, and the company's pre-clinical research product candidates, and for other general corporate purposes, including business expansion activities.

Goldman Sachs & Co LLC, Leerink Partners, BofA Securities, Jefferies and J.P. Morgan are acting as joint book-running managers for the offering. Stifel is acting as co-lead manager for the offering.

Subject to the satisfaction of customary closing conditions, the offering is expected to close on 13 June 2025.